PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: PROK) is a clinical-stage biopharmaceutical company focused on developing cell-based therapies for chronic kidney disease, with its lead program REACT designed to slow the progression of renal function decline. The company entered the public markets in 2022 through a business combination with Social Capital Suvretta Holdings Corp. I, a blank-check vehicle sponsored by Social Capital and Suvretta Capital Management that completed its IPO in 2021. ProKidney filed an 8-K with the SEC on May 29, 2026, under accession number 0001193125-26-248210, disclosing a reportable corporate event. Sign up at SpacDesk for ProKidney's full filing history, deal analytics, and real-time SPAC market data.